OBJECTIVES: Following failure of a @entity902 -antifolate combination regimen, there is no standard therapy for advanced @entity3620 ( @entity3620 ). The fibroblast growth factor receptor (FGFR) signaling pathways may be a relevant target in @entity3620 . @entity36335 inhibits multiple @entity4149 receptor kinases, predominantly the @entity319 ( @entity319 ), but also FGFRs, and could be active in @entity3620 . METHODS: This open-label multicentre phase II trial [NCT01769547] enrolled fit, consenting adult @entity1 with advanced @entity3620 who had previously received @entity902 -antifolate combination chemotherapy and up to one additional line of systemic therapy. @entity36335 was administered orally at 500mg/day for 5days on, 2days off, in 28-day cycles. Response was assessed every 2 cycles using RECIST 1.1 criteria modified for @entity3620 . Correlative studies included @entity7167 amplification on @entity5 and serum samples for circulating angiogenesis factors. The primary end-point was the proportion of @entity1 progression-free at 3 months (PF3) using a two-stage design. RESULTS: 12 @entity1 (10 males, median age 67) were enrolled. The median number of cycles administered was 2.5 (range 1-8). One unconfirmed partial response was observed. PF3 was 50% (95% confidence interval 28.4% to 88.0%); although the criterion for proceeding to stage II accrual was met, the trial was halted due to a combination of minimal activity with several early progression events and poor tolerability in this @entity1 population. One of 12 @entity5 specimens had low amplification of @entity7167 . CONCLUSIONS: @entity36335 has minimal activity in previously-treated @entity3620 . The role of the FGFR pathway in @entity3620 remains unclear.

A phase II trial of XXXX in previously-treated advanced pleural mesothelioma: The Ontario Clinical Oncology Group.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity5 :: ('MESH:D009369', 'Disease') :: ['archival tumour', 'tumour'] @entity319 :: ('3791', 'Gene') :: ['vascular endothelial growth factor receptors', 'VEGFR'] @entity3620 :: ('MESH:C562839', 'Disease') :: ['MPM', 'malignant pleural mesothelioma'] @entity36335 :: ('MESH:C500007', 'Chemical') :: ['Dovitinib'] @entity7167 :: ('2260', 'Gene') :: ['FGFR-1'] @entity4149 :: ('D014443', 'Chemical') :: ['tyrosine'] @entity902 :: ('MESH:D010984', 'Chemical') :: ['platinum']
@entity36335 :: (MESH:C500007,Chemical) :: ['dovitinib']
